Skip to main content

Pharmaceutical Pipeline

Pharmaceutical Pipeline

Yale is committed to advancing healthcare through groundbreaking technologies and discoveries. Explore a diverse array of pioneering projects that span the entire drug development process, from early-stage research to clinical trials. With a focus on addressing critical medical challenges, Yale's Pharmaceutical Pipeline showcases the collective expertise and dedication of our researchers who are aiming to bring tangible solutions to market for patients worldwide.

Device Diagnostic

Device Diagnostic

Preclinical

RIG-101
Licensees:
  • RIGImmune
Areas of Focus
  • Oncology
Troxatyl
Licensees:
  • Beijing HebaBiz
Mucosal covid vaccine
Licensees:
  • Xanadu Bio
EGFR-Her2 vaccine
Licensees:
  • Therajan
IMM-01
Licensees:
Indication

Cancer

LN001
Indication

Multiple Sclerosis

PAT-DX1
Licensees:
Indication

Cancer

PAT-DX1-NP
Licensees:
Indication

Cancer

CPE-54
Licensees:
Indication

Ovarian Cancer

TLC1235
Indication

Mitochondrial Protonophores

CBX-13
Licensees:
Indication

Oncology

CBX-14
Licensees:
Indication

Oncology

CBX-11
Licensees:
Indication

Oncology

Phase I

HLX-55 (fka KTN0216)
Licensees:
PTX-100
Licensees:
  • Prescient
BHV-1300
Licensees:
Indication

Molecular Degraders of Extracellular Proteins (“MoDE™”) are bispecific molecules that target pathologic circulating proteins and direct them to the liver (or other organ systems) for degradation by the endosomal/lysosomal pathway---a novel, competitive platform with a differentiated profile relative to FcRN inhibitors. Specifically, high circulating levels of antibodies (monoclonal or polyclonal gammopathy) drive conditions such as myasthenia gravis, rheumatoid arthritis, systemic lupus erythematosus, pemphigus vulgaris, and many other diseases. 

Areas of Focus
  • Discovery Platform
  • Inflammatory
  • Therapeutics
HLD-0915
Licensees:
  • Halda Therapeutics
BCSZ110
Licensees:
  • Dynamicure
ALX-001
Licensees:
Indication

Alzheimer's

YPT-01
Licensees:
Indication

Infection CF

Anti-ICOS
Licensees:
Indication

Oncology

BHV-1100
Indication

Oncology

OTX-0205
Licensees:
Indication

Chemotherapy-Induced Peripheral Neuropathy ("CIPN")

DCBY02
Licensees:
Indication

Advanced Cancers

TLC6740
Indication

Mitochondrial Protonophores

CBX-12
Licensees:
Indication

Oncology

Phase II

CDX0159
Indication

Inflammation

ARV-766-mCRPC
Licensees:
Indication

Prostate Cancer

NC318
Licensees:
Indication

Cancer

Areas of Focus
  • Oncology
YIV906
Licensees:
Indication

Chemotherapy / Diarrhea

Areas of Focus
  • Oncology
OBP-601/ Censavudine
Licensees:
Indication

HIV

TRXE-002
Indication

OvarianCancer

Areas of Focus
  • Oncology
ST-067
Indication

Immunobiology/ Oncology

QXT-101
Licensees:
Indication

COVID-19

TPN-101 (OBP-101 fka)
Indication

Neurodegeneration

ARV-110
Licensees:
  • Arvinas
Indication

Prostate Cancer

Areas of Focus
  • Oncology

Phase III

ARV-471
Licensees:
  • Arvinas
Areas of Focus
  • Breast Cancer
INZ-701 - ENPPI Deficiency
Licensees:
Indication

Our lead candidate, INZ-701, is in clinical development for the potential treatment of ENPP1 Deficiency and ABCC6 Deficiency, which are driven by low levels of inorganic pyrophosphate (PPi) andadenosine. Currently, there are no therapeutic options for patients suffering from ENPP1 Deficiency and ABCC6 Deficiency –  two rare disorders. We are pioneering the development of effective therapies for these patients and their families.

Market

Spravato
Licensees:
Indication

(Formerly Esketamine)

Depression

Areas of Focus
  • Mental Health
Levovir
Licensees:
Indication

HepatitisB

Areas of Focus
  • Vaccines/Infectious Disease
Zerit®
Licensees:
Indication

HIV/AIDS

Emtrivia™
Licensees:
Indication

HIV/AIDS

Kyprolis
Licensees:
Indication

Cancer

Intuniv
Licensees:
Indication

ADHD

Areas of Focus
  • Mental Health
Lymerix™ (withdrawn)
Licensees:
Indication

Lyme

Areas of Focus
  • Vaccines/Infectious Disease